China The Light In The Tunnel? Merck Thinks So
Market Delivers 17% Growth
Executive Summary
As the first major country apparently emerging from the coronavirus outbreak, China offers a ray of hope for healthcare companies struggling with a large drop in prescriptions and vaccine use as the outbreak continues to wreak havoc in the US, Europe, Japan and emerging markets.
You may also be interested in...
Merck Cuts Pharma Revenue Guidance By $1.7bn Due To Pandemic
Overall, the pharma lowered its 2020 revenue guidance by $2.5bn at the midpoint, but also says it will save about $400m on SG&A expenses. Pandemic impacts expected mainly in Q2, normal resumption in Q4.
China Shines For Lilly Despite Cloudy Volume Purchasing, COVID-19 Forecast
Lilly for the first time breaks out its China business after reporting whopping 93% volume growth in Q1 and a 30% rise in constant currency terms in the first major coronavirus-stricken country.
China Regulatory Express: Biosecurity Law, Export Controls And The Life Science Sector
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Need a specific report? 1000+ reports available
Buy Reports